Akeso, Summit say ivonescimab hit the OS bar in China's Phase 3 HARMONi-2 trial vs. Keytruda; full data due at a future meeting.
After an interim overall survival result last year that shook investor confidence, Akeso has claimed victory Thursday with updated China-only Phase 3 data for its …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Akeso and its partner Summit Therapeutics proclaimed on Tuesday that their high-profile PD-1xVEGF bispecific hit a major Phase 3…
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important…
Summit's ivonescimab cuts death risk 24% (HR 0.76) in Western NSCLC patients at the 2-year HARMONi mark, but median survival…
Summit Therapeutics shares updated Phase 3 data, revealing improving overall survival trends for lung cancer therapy ivonescimab.
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line…
